NCT01407679View on ClinicalTrials.gov

Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Lupus Erythematosus, Cutaneous
Interventions
DRUG

Alitretinoin

1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur

Trial Locations (3)

48149

Department of Dermatology, University Hospital, Münster

68167

Department of Dematology, University Hospital, Mannheim

80337

Department of Dermatology, Ludwig-Maximilians University, Munich

Sponsors
All Listed Sponsors
collaborator

Basilea Pharmaceutica International Ltd

INDUSTRY

lead

University Hospital Muenster

OTHER

NCT01407679 - Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus | Biotech Hunter | Biotech Hunter